You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Repligen Corporation issued $1.0 billion of 0.25% Convertible Senior Notes due 2031 on November 6, 2026, raising approximately $458.6 million in cash and exchanging approximately $456.8 million principal of 2028 Notes.
Repligen completed the BioLife acquisition for approximately $1.9 billion on October 6, 2026. Nine-month product revenue rose 12.5%, while Repligen recorded a $41.2 million intangible asset impairment charge.
Repligen Corporation announced $1.0 billion of 0.25% Convertible Senior Notes due 2031, comprising $541.4 million exchanged for $456.8 million of 2028 Notes and $458.6 million issued for cash; closing is expected on or about November 6, 2026.
Repligen reported third-quarter revenue of $209 million and raised 2026 revenue guidance to $844 to $852 million. For 2027, it expects reported growth of at least 25% and revenue exceeding US$1 billion.
Repligen reported Q3 revenue of $209.3 million, up 11% as reported and 12.5% organically, completed the BioLife acquisition on October 6, 2026, and raised FY 2026 reported revenue guidance to $844M - $852M, representing 14.5% - 15.5% growth.
Repligen Corporation completed its acquisition of BioLife Solutions, Inc. on October 6, 2026, making BioLife a wholly owned subsidiary; BioLife stockholders received $11.25 per share in cash and 0.1442 Repligen shares, and BioLife common stock was delisted from Nasdaq.
